Savara Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Savara Inc. on June 1, 2020, covering events occurring between May 27 and May 29, 2020. The report details executive appointments, compensation approvals, and the results of the annual stockholder meeting.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses on corporate governance and compensation structures.
Material Changes and Corporate Actions
- Executive Appointment: On May 27, 2020, Taneli Jouhikainen was appointed Chief Business Officer while continuing as President, transitioning from his previous role as Chief Operating Officer.
- Compensation Approval: The Board approved 2020 target bonus amounts for executive officers, which remain unchanged from 2019 levels except for the Chief Medical Officer who joined in late 2019.
- Equity Plan Amendment: Stockholders approved an amendment to the 2015 Omnibus Incentive Plan, increasing the authorized share count by 3,500,000.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance or specific risk disclosures. It notes that actual bonus payments are contingent on achieving performance goals and are subject to Board discretion.
Investor Verification Checklist
- Verify the impact of the 3,500,000 share increase on existing shareholder dilution.
- Review the specific performance metrics tied to the executive bonus structure (25% corporate, 50% individual, 25% CEO discretion for most officers).
- Confirm the voting results for the ratification of RSM US LLP as the independent auditor.
- Monitor the transition of Taneli Jouhikainen into the new Chief Business Officer role.
Executive Compensation Targets (2020)
| Executive Officer | Title | Target Bonus Amount | % of Base Salary |
|---|---|---|---|
| Rob Neville | Chief Executive Officer | $273,000 | 50% |
| Taneli Jouhikainen | President and Chief Business Officer | $273,000 | 50% |
| Badrul Chowdhury | Chief Medical Officer | $210,000 | 40% |
| Dave Lowrance | Chief Financial Officer | $151,840 | 40% |
Annual Meeting Voting Results
All director nominees were elected. Key proposals passed as follows:
- Equity Plan Amendment: Approved (21,361,131 For vs. 866,911 Against).
- Auditor Ratification: Approved (34,137,758 For vs. 742,811 Against).
- Executive Compensation Advisory Vote: Approved (21,425,373 For vs. 762,427 Against).